Cognitive impairment in diabetic patients: Can diabetic control prevent cognitive decline?

Journal of Diabetes Investigation

Volumn 3, Issue 5, 2012, Pages 413-423

  Kawamura, Takahiko ^a   Umemura, Toshitaka ^a   Hotta, Nigishi ^a  

^a CHUBU ROSAI HOSPITAL   (Japan)

Author keywords

Cognitive function; Diabetes mellitus; Glycemic control

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE;

AGING; ALZHEIMER DISEASE; BLOOD PRESSURE REGULATION; CAREGIVER BURDEN; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; DEMENTIA; DEPRESSION; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE DURATION; GENETIC POLYMORPHISM; GERIATRIC PATIENT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HORMONE ACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LABORATORY TEST; LIFESPAN; LIFESTYLE MODIFICATION; LONGITUDINAL STUDY; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NEUROIMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84867824917     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2012.00234.x     Document Type: Review

References (109)

1. Hotta N, Nakamura J, Iwamoto Y, et al. Causes of death in Japanese diabetics: a questionnaire survey of 18, 385 diabetics over a 10-year period. J Diabetes Invest 2010; 1: 66-76.
2. Luengo-Fernandez R, Leal J, Gray AM. Cost of dementia in the pre-enlargement countries of the European Union. J Alzheimers Dis 2011; 27: 187-196.
3. Yoshitake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: The Hisayama Study. Neurology 1995; 45: 1161-1168.
4. Leibson CL, Rocca WA, Hanson VA, et al. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 1997; 145: 301-308.
5. Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia. The Rotterdam Study. Neurology 1999; 53: 1937-1942.
6. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies. The Honolulu-Asia Aging Study. Diabetes 2002; 51: 1256-1262.
7. Ohara T, Doi Y, Ninomiya T, et al. Glucose tolerance status and risk of dementia in the community. The Hisayama Study. Neurology 2011; 77: 1126-1134.
8. Biessels GJ, Staekenborg S, Brunner E, et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64-74.
9. The Diabetes Control and Complication Trial/Epidemiology of Diabetes Intervention and Complications (DCCT/EDIC) Study Research Group. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007; 356: 1842-1852.
10. Jacobson AM, Ryan CM, Cleary PA, et al. Biomedical risk factors for decreased cognitive functioning in type 1 diabetes: an 18 year follow-up of diabetes control and complications trial (DCCT) cohort. Diabetologia 2011; 54: 233-236.
11. Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomized open-label substudy. Lancet Neurol 2011; 10: 969-977.
12. Christman AL, Matsushita K, Gottesman RF, et al. Glycated haemoglobin and cognitive decline: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia 2011; 54: 1645-1653.
13. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American heart association/American stroke association. Stroke 2011; 42: 2672-2713.
14. Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes-systematic overview of prospective observational studies. Diabetologia 2005; 48: 2460-2469.
15. Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocr Rev 2008; 29: 494-511.
16. Munshi M, Grande L, Hayes M, et al. Cognitive dysfunction is associated with poor diabetes control in older adults. Diabetes Care 2006; 29: 1794-1799.
17. Cukierman-Yaffe T, Gerstein HC, Williamson JD, et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors. The Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) trial. Diabetes Care 2009; 32: 221-226.
18. Umegaki H, Kawamura T, Mogi N, et al. Glucose control levels, ischaemic brain lesions, and hyperinsulinaemia were associated with cognitive dysfunction in diabetic elderly. Age Ageing 2008; 37: 458-461.
19. Strachan MWJ. The brain as a target organ in Type 2 diabetes: exploring the links with cognitive impairment and dementia. Diabet Med 2011; 28: 141-147.
20. Heikkiä O, Lundbom N, Timonen M, et al. Hyperglycaemia is associated with changes in the regional concentrations of glucose myo-inositol within the brain. Diabetologia 2009; 52: 534-540.
21. Lyoo IK, Yoon SJ, Musen G, et al. Altered prefrontal glutamate-glutamine-γ-aminobutyric acid levels and relation to low cognitive performance and depressive symptoms in Type 1 diabetes mellitus. Arch Gen Psychiatry 2009; 66: 878-887.
22. Bruce DG, Davis WA, Casey GP, et al. Predictors of cognitive impairment and dementia in older people with diabetes. Diabetologia 2008; 51: 241-248.
23. Yaffe K, Blackwell T, Whitmer RA, et al. Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Aging 2006; 10: 293-295.
24. Umegaki H, Kawamura T, Kawano N, et al. Factors associated with cognitive decline in elderly diabetics. Dement Geriatr Cogn Disord Extra 2011; 1: 1-9.
25. Imamine R, Kawamura T, Umemura T, et al. Does cerebral small vessel disease predict future decline of cognitive function in elderly patients with type 2 diabetes? Diabetes Res Clin Pract 2011; 94: 91-99.
26. Perantie DC, Koller JM, Weaver PM, et al. Prospectively determined impact of Type 1 diabetes on brain volume during development. Diabetes 2011; 60: 3006-3014.
27. Smith EE, Egorova S, Blacker D, et al. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Arch Neurol 2008; 65: 94-100.
28. Euser SM, Sattar N, Wittman CM, et al. A prospective analysis of elevated fasting glucose levels and cognitive function in older people. Results from PROSPER and the Rotterdam study. Diabetes 2010; 59: 1601-1607.
29. Kwok C-F, Ho L-T. Severe hypoglycemia predicts major adverse outcomes in diabetic patients undergoing glycemic control regimes. J Diabetes Invest 2012; 3: 34-35.
30. Araki A, Ito H. Diabetes mellitus and geriatric syndromes. Geriatr Gerontol Int 2009; 9: 105-114.
31. Rizzo MR, Marfella R, Barbieri M, et al. Relationships between daily acute glucose fluctuations and cognitive performance among aged Type 2 diabetic patients. Diabetes Care 2010; 33: 2169-2174.
32. Abbatecola AM, Rizzo MR, Barbieri M, et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006; 67: 235-240.
33. Schuur M, Henneman P, van Swieten JC, et al. Insulin-resistance and metabolic syndrome are related to executive function in women in a large family-based study. Eur J Epidemiol 2010; 25: 561-568.
34. Raffaitin CR, Féart C, Le Goff M, et al. Metabolic syndrome and cognitive decline in French elders. The Three-City Study. Neurology 2011; 76: 518-525.
35. Whitmer RA. Type 2 diabetes and risk of cognitive impairment and dementia. Curr Neurol Neurosci Rep 2007; 7: 373-380.
36. Logroscino G, Kang JH, Grodstein F. Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. BMJ 2004; 328: 5480.
37. Ryan CM, Fried MI, Rood JA, et al. Improving metabolic control leads to better working memory in adults with Type 2 diabetes. Diabetes Care 2006; 29: 345-351.
38. Wu JH, Haan MN, Liang J, et al. Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study. Ann Epidemol 2003; 13: 369-376.
39. Himeno T, Kamiya H, Naruse K, et al. Benefical effects of Exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes 2011; 60: 2397-2406.
40. Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. J Clin Invest 2012; 122: 1339-1353.
41. Mogi N, Umegaki H, Hattori A, et al. Cognitive function in Japanese elderly with type 2 diabetes mellitus. J Diabetes Complications 2004; 18: 42-46.
42. Feil DG, Rajan M, Soroka O, et al. Risk of hypoglycemia in older veterans with dementia and cognitive impairment: implications for practice and policy. J Am Geriatr Soc 2011; 59: 2263-2272.
43. Craft S. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related on memory, amyloid, and inflammation. Neurobiol Aging 2005; 26S: S65-S69.
44. Young SE, Mainous AG, Carnemolla M. Hyperinsulinemia and cognitive decline in a middle-aged cohort. Diabetes Care 2006; 29: 2688-2693.
45. Matsuzaki T, Sasaki K, Tanizaki Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease. The Hisayama Study. Neurology 2010; 75: 764-770.
46. Rönnenmaa E, Zethelius B, Sundelöf J, et al. Impaired insulin secretion increased the risk of Alzheimer disease. Neurology 2008; 71: 1065-1071.
47. Rönnenmaa E, Zethelius B, Sundelöf J, et al. Glucose metabolism and the risk of Alzheimer's disease and dementia: a population-based 12 years follow-up study in 71-years-old men. Diabetologia 2009; 52: 1504-1510.
48. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry 2010; 67: 505-512.
49. Sturman MT, Mendes de Leon CF, Bienias JL, et al. Body mass index and cognitive decline in a biracial community population. Neurology 2008; 70: 360-367.
50. Siervo M, Arnold R, Wells JCK, et al. Intentional weight loss in overweight and obese individuals and cognitive function: a systematic review and meta-analysis. Obes Rev 2011; 12: 968-983.
51. Abbatecola AM, Lattanzio F, Molinari AM, et al. Rosiglitazone and cognitive stability in older individuals with Type 2 diabetes and mild cognitive impairment. Diabetes Care 2010; 33: 1706-1711.
52. Sato T, Hanyu H, Hirao K, et al. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 2011; 32: 1626-1633.
53. Shemesh E, Rudich A, Harman-Boehm I, et al. Effect of intranasal insulin on cognitive function-A systematic review. J Clin Endocrinol Metab 2012; 97: 366-376.
54. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment. Arch Neurol 2012; 69: 29-38.
55. Bruce DG, Davis WA, Casey GP, et al. Severe hypoglycemia and cognitive impairment in older patients with diabetes: the Fremantle Diabetes Study. Diabetologia 2009; 52: 1808-1815.
56. Whitmer RA, Karter AJ, Yaffe K, et al. Hypoglycemic episodes and risk of dementia in older patients with Type 2 diabetes mellitus. JAMA 2009; 301: 1565-1572.
57. Åsvold BO, Sand T, Hestad K, et al. Cognitive function in Type 1 diabetic adults with early exposed to severe hypoglycemia. A 16-year follow-up study. Diabetes Care 2010; 33: 1945-1947.
58. Punthakee Z, Miller ME, Launer LJ, et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes. Post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care 2012; 35: 787-793.
59. Wessels AM, Rombouts SARB, Simsek S, et al. Microvascular disease in type 1 diabetes alters brain activation. A functional magnetic resonance imaging study. Diabetes 2006; 55: 334-340.
60. Wessels AM, Simsek S, Remijinse PL, et al. Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. Diabetologia 2006; 49: 2474-2480.
61. Ding J, Strachan MWJ, Reynolds RM, et al. Diabetic retinopathy and cognitive decline in older people with type 2 diabetes. The Edinburgh type 2 diabetes study. Diabetes 2010; 59: 2883-2889.
62. de Bresser J, Reijmer YD, van den Berg E, et al. Microvascular determinants of cognitive decline and brain volume change in elderly patients with type2 diabetes. Dement Geriatr Cogn Disord 2010; 30: 381-386.
63. Kwa VI, van der Sande JJ, Stam J, et al. Retinal arterial changes correlate with cerebral small-vessel disease. Neurology 2002; 59: 1536-1540.
64. Lesage SR, Mosley TH, Wong TY, et al. Retinal microvasuclar abnormalities and cognitive decline. The ARIC 14-year follow-up study. Neurology 2009; 73: 862-868.
65. Haan M, Espeland MA, Klein BE, et al. Cognitive function and retinal and ischemic brain changes. The Women's Health Initiative. Neurology 2012; 78: 942-949.
66. Weiner DE, Bartolomei K, Scott T, et al. Albuminuria, cognitive functioning, and white matter hyperintensities in Homebound Elders. Am J Kidney Dis 2009; 53: 438-447.
67. Ito S, Nagasawa T, Abe M, et al. Strain vessel hypothesis: a viewpoint for linkage of albuminuria and cerebro-cardiovascular risk. Hypertens Res 2009; 32: 115-121.
68. Ryan CM. Diabetes, aging, and cognitive decline. Neurobiol Aging 2005; 26S: S21-S25.
69. Manschot SM, Biessels GJ, Rutten GEHM, et al. Peripheral and central neurologic complications in type 2 diabetes mellitus: no association in individual patients. J Neuro Sci 2008; 264: 157-162.
70. Kawamura T, Umemura T. Is cognitive impairment the fourth diabetic microvascular complication? J Diabetes Invest 2011; 2: 351-353.
71. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010; 341: c3666.
72. Patel B, Markus HS. Magnetic resonance imaging in ceregral small vessel disease and its use as a surrogate disease marker. Int J Stroke 2011; 6: 47-59.
73. Werring DJ, Gregoire SM, Cipolotti L. Cerebral microbleeds and vascular cognitive impairment. J Neurol Sci 2010; 299: 131-135.
74. van Harten B, Scheltens P, de Leeuw FE, et al. Brain imaging in patients with diabetes. A systematic review. Diabetes Care 2006; 29: 2539-2548.
75. Smith EE, Salat DH, Jeng J, et al. Correlation between MRI white matter lesion location and excutive function and episodic memory. Neurology 2011; 76: 1492-1499.
76. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol Aging 2009; 30: 337-352.
77. Kawamura T, Umemura T, Kanai A, et al. The incidence and characteristics of silent cerebral infarction in elderly diabetic patients: association with serum-soluble adhesion molecules. Diabetologia 1998; 41: 911-917.
78. Kawamura T, Umemura T, Kanai A, et al. Soluble adhesion molecules and C-reactive protein in the progression of silent cerebral infarction in patients with type 2 diabetes mellitus. Metabolism 2006; 55: 461-466.
79. Umemura T, Kawamura T, Umegaki H, et al. Endothelial and inflammatory markers in relation to progression of ischaemic cerebral small-vessel disease and cognitive impairment: a 6-year longitudinal study in patients with type 2 diabetes mellitus. J Neurol Neurosurg Pshychiatry 2011; 82: 1186-1194.
80. Hoth KF, Tate DF, Poppas A, et al. Endothelial function and white matter hyperintensities in older adults with cardiovascular disease. Stroke 2007; 38: 308-312.
81. Barnes D, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011; 10: 819-828.
82. Ritchie K, Carriérw I, Ritchie CW, et al. Designing prevention program to reduce incidence of dementia: prospective cohort study of modifiable risk factors. BMJ 2010; 341: c3885.
83. Alonso A, Mosley TH Jr, Gottesman RF, et al. Risk of dementia hospitalization associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study. J Neurol Neurosurg Psychiatry 2009; 80: 1194-1201.
84. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005; 4: 487-499.
85. Li N-C, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465.
86. Haag MDM, Hofman A, Koudstaal PJ, et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 2009; 80: 13-17.
87. Wu JH, Hann MN, Liang J, et al. Impact of diabetes on cognitive function among older Latinos. A population-based cohort study. J Clin Epidemol 2003; 56: 686-693.
88. Pan A, Lucas M, Sun Q, et al. Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med 2010; 170: 1884-1891.
89. Katon W, Lyles CR, Parker MM, et al. Association of depression with increased risk of dementia in patients with type 2 diabetes. The Diabetes and Aging Study. Arch Gen Psychiatry 2012; 69: 410-417.
90. Strachan MWJ, Reynolds RM, Marioni RE, et al. Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol 2011; 7: 108-114.
91. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009; 63: 287-303.
92. Dore GA, Elias MF, Robbins MA, et al. Presence of APOE ε4 allele modifies the relationship between type 2 diabetes and cognitive performance: the Maine-Syracuse Study. Diabetologia 2009; 52: 2551-2560.
93. Irie F, Fitzpatrick AL, Lopez OL, et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE ε4. The Cardiovascular Health Study Cognition Study. Arch Neurol 2008; 65: 89-93.
94. Ahtiluoto S, Polvikoski T, Peltonen M, et al. Diabetes, Alzheimer disease, and vascular dementia. A population-based neuropathologic study. Neurolgy 2010; 75: 1195-1202.
95. Nielson KA, Nolan JH, Berchtold NC, et al. Apolipoprotein-E genotyping of diabetic dementia patients: is diabetes rare in Alzheimer's disease? J Am Geriatr Soc 1996; 44: 897-904.
96. Blair CK, Folsom AR, Knopman DS, et al. APOE genotype and cognitive decline in a middle-aged cohort. Neurology 2005; 64: 268-276.
97. Gæde P, Lund-Andersen H, Parving H-H, et al. Effect of multifactorial intervention on mortality in Type 2 diabetes. N Engl J Med 2008; 358: 580-591.
98. Noto H, Tsujimoto T, Noda M. Significantly increased risk of cancer in diabetes mellitus patients: a meta-analysis of epidemiological evidence in Asia an non-Asias. J Diabetes Invest 2012; 3: 24-33.
99. Driver JA, Beiser A, Au R, et al. Inverse association between cancer and Alzheimer's disease: result from the Framingham Heart Study. BMJ 2012; 344: e1442.
100. Xu W, Caracciolo B, Wang H-X, et al. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 2010; 59: 2928-2935.
101. Ruis C, Biessels GJ, Gorter KJ, et al. Cognition in the early stage of type 2 diabetes. Diabetes Care 2009; 32: 1261-1265.
102. Alencar RC, Cobas RA, Gomes MB. Assessment of cognitive status in patients with type 2 diabetes through the mini-mental status examination: a cross-sectional study. Diabetol Metab Syndr 2010; 2: 10.
103. Kamiyama K, Wada A, Sugiura M, et al. Potential hippocampal region atrophy in diabetes mellitus type 2: a voxel-based morphometry VSRAD study. Jpn J Radiol 2010; 28: 266-272.
104. Anan F, Masaki T, Shimomura T, et al. High-sensitivity C-reactive protein is associated with hippocampus volume in nondementia with type 2 diabetes mellitus. Metabolism 2011; 60: 460-466.
105. Tan ZS, Beiser AS, Vasan RS, et al. Inflammatory markers and the risk of Alzheimer disease. The Framingham Study. Neurology 2007; 68: 1902-1908.
106. Hoshi T, Yamagami H, Furukado S, et al. Serum inflammatory proteins and frontal lobe dysfunction in patients with cardiovascular risk factors. Eur J Neurol 2010; 17: 1134-1140.
107. O'Bryant SE, Xiao G, Barber R, et al. A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 2010; 67: 1077-1081.
108. van Himbergen TM, Beiser AS, Ai M, et al. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease. Results from the Framingham Heart Study. Arch Neurol 2012; 69: 594-600.
109. Vidoni ED, Townley RA, Honea RA, et al. Alzheimer disease biomarkers are associated with body mass index. Neurology 2011; 77: 1913-1920.